Zelluna Immunotherapy As (private company)

See something wrong or missing? Let us know
Offices:
Oslo
Business model:
B2B
Investors:
we tracked 6 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.

Companies with similar profile to Zelluna Immunotherapy As:

CompanyCriteria
Norway Oncoinvent
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one other investor: Geveran Trading
  • Minim one investor from outside Scandinavia: Yes
Norway APIM Therapeutics
46%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Ro Invest, Birk Venture
Spain Pulmobiotics S.L
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Chundsell Medicals
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland FinnAdvance
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain InnoUp Farma
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Sigrid Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Polimerbio
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark AFYX Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Sanifit Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Optomed
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Gyala Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Galecto Biotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Particle 3D
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Aprea Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Elypta
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Iceland Alvotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark STipe Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Octarine Bio
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes